📣 VC round data is live. Check it out!
- Public Comps
- Artrya
Artrya Valuation Multiples
Discover revenue and EBITDA valuation multiples for Artrya and similar public comparables like Heren Health, Weave Communications, GPI Group, Veradigm and more.
Artrya Overview
About Artrya
Artrya Ltd is a medical technology company. The company is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. It is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.
Founded
2018
HQ

Employees
43
Website
Sectors
Financials (LTM)
EV
$452M
Valuation Multiples
Start free trialArtrya Financials
Artrya reported last 12-month revenue of $4M and negative EBITDA of ($13M).
In the same LTM period, Artrya generated $4M in gross profit, ($13M) in EBITDA losses, and had net loss of ($14M).
Revenue (LTM)
Artrya P&L
In the most recent fiscal year, Artrya reported revenue of $20K and EBITDA of ($10M).
Artrya is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (47790%), and net margin of (52270%).
Financial data powered by Morningstar, Inc.
Artrya Stock Performance
Artrya has current market cap of $507M, and enterprise value of $452M.
Market Cap Evolution
Artrya's stock price is $3.16.
Artrya share price increased by 11.7% in the last 30 days, and by 485.3% in the last year.
Artrya has an EPS (earnings per share) of $-0.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $452M | $507M | -1.9% | 11.7% | 29.6% | 485.3% | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArtrya Valuation Multiples
Artrya trades at 113.4x EV/Revenue multiple, and (33.8x) EV/EBITDA.
EV / Revenue (LTM)
Artrya Financial Valuation Multiples
As of May 7, 2026, Artrya has market cap of $507M and EV of $452M.
Artrya has a P/E ratio of (36.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Artrya Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Artrya Margins & Growth Rates
Artrya grew revenue by 23053% and EBITDA by 45% in the last fiscal year.
In the most recent fiscal year, Artrya reported gross margin of 100%, EBITDA margin of (47790%), and net margin of (52270%).
Artrya Margins
Artrya Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Artrya Operational KPIs
Artrya's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Artrya's Rule of 40 is 147% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Artrya's Rule of X is 555% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Artrya Competitors
Artrya competitors include Heren Health, Weave Communications, GPI Group, Veradigm, Echo IQ, Claritev, Beijing Sunwayworld, Medley Inc., Phreesia and Medical Data Vision.
Most Artrya public comparables operate across Healthcare Software.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 7.1x | — | 37.9x | — | |||
| 1.9x | 1.8x | (43.1x) | 42.0x | |||
| 1.4x | 1.4x | 7.0x | 6.7x | |||
| 0.5x | 0.5x | 5.3x | 3.9x | |||
| 6145.6x | 652.1x | (105.5x) | (105.2x) | |||
| 5.2x | 5.2x | 10.8x | 8.3x | |||
| 7.3x | — | 126.8x | — | |||
| 2.0x | 1.8x | 15.1x | 14.1x | |||
This data is available for Pro users. Sign up to see all Artrya competitors and their valuation data. Start Free Trial | ||||||
Artrya Funding History
Before going public, Artrya raised $15M in total equity funding, across 1 round.
Artrya Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Artrya
| When was Artrya founded? | Artrya was founded in 2018. |
| Where is Artrya headquartered? | Artrya is headquartered in Australia. |
| How many employees does Artrya have? | As of today, Artrya has over 43 employees. |
| Is Artrya publicly listed? | Yes, Artrya is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Artrya? | Artrya trades under AYA ticker. |
| When did Artrya go public? | Artrya went public in 2021. |
| Who are competitors of Artrya? | Artrya main competitors include Heren Health, Weave Communications, GPI Group, Veradigm, Echo IQ, Claritev, Beijing Sunwayworld, Medley Inc., Phreesia, Medical Data Vision. |
| What is the current market cap of Artrya? | Artrya's current market cap is $507M. |
| What is the current revenue of Artrya? | Artrya's last 12 months revenue is $4M. |
| What is the current revenue growth of Artrya? | Artrya revenue growth (NTM/LTM) is 191%. |
| What is the current EV/Revenue multiple of Artrya? | Current revenue multiple of Artrya is 113.4x. |
| Is Artrya profitable? | No, Artrya is not profitable. |
| What is the current EBITDA of Artrya? | Artrya has negative EBITDA and is not profitable. |
| What is Artrya's EBITDA margin? | Artrya's last 12 months EBITDA margin is (336%). |
| What is the current EV/EBITDA multiple of Artrya? | Current EBITDA multiple of Artrya is (33.8x). |
| What is the current FCF of Artrya? | Artrya's last 12 months FCF is ($13M). |
| What is Artrya's FCF margin? | Artrya's last 12 months FCF margin is (318%). |
| What is the current EV/FCF multiple of Artrya? | Current FCF multiple of Artrya is (35.7x). |
| How many companies Artrya has acquired to date? | Artrya hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Artrya has invested to date? | Artrya hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Artrya
Lists including Artrya
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.